Healthcare Contract Research Outsourcing Market share globally was worth USD 73.11 billion in 2024 and is anticipated to grow ...

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of MedicineResults support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in ...

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients ...

Kelso Pharma builds for future growth with appointment of life sciences leader as Chief Operating OfficerKelso Pharma, the growing UK-based specialty pharmaceuticals business, has appointed life ...

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) Research conducted in collaboration with IPF experts and the ...

Financial Results and Highlights of Recent Company Progress~ AMT-130 granted Breakthrough Therapy designation by FDA ~~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues ...

Acquisition Bolsters Aspire’s Strategic PortfolioPetersfield, Hampshire, 8th May 2025, Aspire Pharma Limited, a rapidly growing UK-based specialty niche generics business, announces the bolstering of ...

Health Net Connections LTD (HNC) providers of healthcare technology to hospitals, doctors surgeries and private clinics across the UK & Europe has appointed Faith Bose as its new UK sales director.

Theriva Biologics Announces Closing of $7.5 Million Public OfferingROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified ...

May 2025 £5m project aims to make Liverpool global leader in biologics A new project led by Liverpool School of Tropical Medicine (LSTM) will enable the seamless translation of innovative vaccine and ...

Onctura commences randomized Phase I/II study in non-small cell lung cancer First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have ...

YEMASSEE, SC / ACCESS Newswire / May 8, 2025 / Dr. Greg Westergaard, CEO of Alpha Genesis Incorporated (AGI), today ...